Reistone Reports Positive Results from Trial of JAK1 Inhibitor for Alopecia Areata
publication date: Aug 24, 2021
Shanghai Reistone Biopharma reported positive results from a Phase II trial of its JAK1 inhibitor for alopecia areata, an autoimmune disease. Two doses of once-daily SHR0302 showed a statistically significant percentage change of SALT score, a quantitative indicator of AA severity based on scalp hair loss. Reistone in-licensed the JAK1 inhibitor from Jiangsu Hengrui, which also backs Reistone. Formed in January 2018, Reistone focuses on globalizing innovative drugs developed in China. The Phase II trial was conducted in Australia, China and the US. More details....
Stock Symbol: (SHA; 600276)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.